Gapping up
In reaction to earnings/guidance:
- ANET +9.9%, CPSS +9%, RLGT +8.7%, AMKR +8.7%, ALLE +8.2%, ARCH +6.8%, ABG +5.9%, OTTR +5.3%, TNET +4.6% (also stock repurchase program increased by $300 mln), HSIC +3.6%, TRTN +3.5%, WCC +3.4%, KRG +2.9% (also increases dividend), HUN +2.6%, CEVA +2.6%, POWW +2.4%, MAR +2.4%, BWA +1.7%, IQV +1.7%, SCI +1.6%, ZTS +1.6%, SAFE +1.5%, CAR +1.4%, QSR +1.4%, NTB +1% (also announces new 2 mln share repurchase program)
Other news:
- TSEM +41.9% (to be acquired by Intel (INTC) for $53.00 per share in cash)
- IBRX +12.5% (announces positive data from bladder cancer trial)
- SPCE +12.4% (to open ticket sales to the general public starting February 16)
- JOBY +9.5% (announces partnership with ANA HOLDINGS to bring air taxi service to Japan)
- DCFC +8.7% (announces a partnership with Wise EV for fast chargers for a new national EV charging network)
- VRAY +7.3% (Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian MRI-guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer)
- AUR +5.3% (AUR and USX announce partnership for the deployment of autonomous trucks)
- QSI +5.1% (names interim CEO)
- TGTX +4.9% (Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum)
- FSR +4.5% (opens reservations for second product the Fisker PEAR)
- MNST +4.2% (MNST in discussions with STZ re possible combination according to Bloomberg)
- AZN +3.4% (LYNPARZA plus Abiraterone reduced risk of disease progression by 34%)
- EXEL +3.3% (BMY and EXEL announce that Opdivo in combination with CABOMETYX demonstrates continued survival benefits)
- VMEO +3.1% (reports performance metrics for January)
- NVAX +3% ( Singapore Health Sciences issues interim authorization for Nuvaxovid)
- NTLA +3% (announces collaboration and licensing agreement with ONK Therapeutics)
- IMGN +2.9% (announces a global multi-year definitive licensing agreement whereby it granted Eli Lilly and Company (LLY) exclusive rights to research develop and commercialize ADCs directed to targets selected by Lilly based on ImmunoGen's novel camptothecin technology)
- SGH +2.7% (names new chair)
- HUN +2.6% (increases dividend)
- GDDY +2.1% (executes $750 million accelerated share repurchase agreements)
- MET +1.8% (aims to sell $1 bln of private-equity assets through secondary sale according to WSJ)
- MRTN +1.7% (expands dry truckload operations into Mexico)
- GS +1.5% (federal investigators are probing block trading on Wall Street according to WSJ)
- LLY +1.4% (awarded $1.08 bln Army contract for Bebtelovimab)
- SWAG +1.1% (announces combination agreement with Nogin)
Analyst comments:
- COLL +4.5% (upgraded to Overweight from Neutral at Cantor Fitzgerald)
- CPA +3.6% (upgraded to Buy from Hold at HSBC Securities)